Angle-closure glaucoma — DVA SoP factors

Reasonable Hypothesis (RH) — Statement of Principles No. 5 of 2021

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting angle-closure glaucoma or death from angle-closure glaucoma with the circumstances of a person's relevant service:

1. (1)
   taking a drug from the specified list of drugs within the 21 days before the clinical onset of angle-closure glaucoma;

   Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

2. (2)
   taking a drug which causes: (a) mydriasis or miosis in the affected eye; or (b) an allergic or inflammatory reaction involving structures of the anterior segment of the affected eye; within the 21 days before the clinical onset of angle-closure glaucoma;
3. (3)
   having uveitis, scleritis or episcleritis at the time of the clinical onset of angle-closure glaucoma, where the disease involves the structures of the anterior chamber of the affected eye;

   Note: uveitis, scleritis and episcleritis are defined in the Schedule 1 - Dictionary.

4. (4)
   having: (a) a benign or malignant neoplasm; or (b) a non-neoplastic lesion; which involves the anterior segment of the affected eye at the time of the clinical onset of angle-closure glaucoma;

   Note: Examples of a benign or malignant neoplasm include melanoma, retinoblastoma, leukaemia and lymphoma.

   Note: Examples of a non-neoplastic lesion include amyloidosis, cyst, ocular haemorrhage, retinal detachment and vascular malformation or thrombosis.

5. (5)
   having a disorder of the lens of the affected eye at the time of the clinical onset of angle-closure glaucoma;

   Note: Examples of a disorder of the lens include cataract and lens displacement, subluxation or dislocation.

6. (6)
   having growth of new blood vessels (neovascularisation) of the iridocorneal angle due to a condition or procedure involving the affected eye from the specified list of conditions or procedures, before the clinical onset of angle-closure glaucoma;

   Note: specified list of conditions or procedures is defined in the Schedule 1 - Dictionary.

7. (7)
   having trauma to the affected eye before the clinical onset of angle-closure glaucoma;

   Note: trauma is defined in the Schedule 1 - Dictionary.

8. (8)
   having sympathetic ophthalmia at the time of the clinical onset of angle-closure glaucoma;

   Note: sympathetic ophthalmia is defined in the Schedule 1 - Dictionary.

9. (9)
   having surgery to the affected eye, or eyelid of the affected eye, before the clinical onset of angle-closure glaucoma;
10. (10)
    having surgery requiring a general anaesthetic, or surgery in the prone position, within the 21 days before the clinical onset of angle-closure glaucoma;
11. (11)
    undergoing a course of therapeutic radiation for cancer, where the affected eye was in the field of radiation, before the clinical onset of angle-closure glaucoma;
12. (12)
    taking a drug from the specified list of drugs within the 21 days before the clinical worsening of angle-closure glaucoma;

    Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

13. (13)
    taking a drug which causes: (a) mydriasis or miosis in the affected eye; or (b) an allergic or inflammatory reaction involving structures of the anterior segment of the affected eye; within the 21 days before the clinical worsening of angle-closure glaucoma;
14. (14)
    having uveitis, scleritis or episcleritis at the time of the clinical worsening of angle-closure glaucoma, where the disease involves the structures of the anterior chamber of the affected eye;

    Note: uveitis, scleritis and episcleritis are defined in the Schedule 1 - Dictionary.

15. (15)
    having: (a) a benign or malignant neoplasm; or (b) a non-neoplastic lesion; which involves the anterior segment of the affected eye at the time of the clinical worsening of angle-closure glaucoma;

    Note: Examples of a benign or malignant neoplasm include melanoma, retinoblastoma, leukaemia and lymphoma.

    Note: Examples of a non-neoplastic lesion include amyloidosis, cyst, ocular haemorrhage, retinal detachment and vascular malformation or thrombosis.

16. (16)
    having a disorder of the lens of the affected eye at the time of the clinical worsening of angle-closure glaucoma;

    Note: Examples of a disorder of the lens include cataract and lens displacement, subluxation or dislocation.

17. (17)
    having growth of new blood vessels (neovascularisation) of the iridocorneal angle due to a condition or procedure involving the affected eye from the specified list of conditions or procedures, before the clinical worsening of angle-closure glaucoma;

    Note: specified list of conditions or procedures is defined in the Schedule 1 - Dictionary.

18. (18)
    having trauma to the affected eye before the clinical worsening of angle-closure glaucoma;

    Note: trauma is defined in the Schedule 1 - Dictionary.

19. (19)
    having sympathetic ophthalmia at the time of the clinical worsening of angle-closure glaucoma;

    Note: sympathetic ophthalmia is defined in the Schedule 1 - Dictionary.

20. (20)
    having surgery to the affected eye, or eyelid of the affected eye, before the clinical worsening of angle-closure glaucoma;
21. (21)
    having surgery requiring a general anaesthetic, or surgery in the prone position, within the 21 days before the clinical worsening of angle-closure glaucoma;
22. (22)
    undergoing a course of therapeutic radiation for cancer, where the affected eye was in the field of radiation, before the clinical worsening of angle-closure glaucoma;
23. (23)
    inability to obtain appropriate clinical management for angle-closure glaucoma;

Aggravation-only factors: the factors in subsections 9(12) to 9(23) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.